Ascletis Pharma Inc. (01672) disclosed a Next Day Disclosure Return dated 31 October 2025. The company repurchased 200,000 ordinary shares on 31 October 2025, representing approximately 0.0202% of its existing issued shares (excluding treasury shares). The transaction took place at a weighted average price of HKD 9.6634 per share, raising the total number of treasury shares to 6,884,210 and leaving the overall issued share count unchanged at 998,958,530.

From 03 April 2025 to 13 October 2025, the company repurchased a total of 960,000 shares for cancellation, which remain uncancelled as of 31 October 2025. According to the repurchase report, as of 31 October 2025, Ascletis Pharma Inc. has repurchased an aggregate of 1,260,000 shares under a mandate dated 22 May 2025, representing 0.1308% of the issued shares at the time the mandate was granted. The reported data also indicate a moratorium period on the issuance or transfer of shares until 30 November 2025.